# Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

> **NCT01011920** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 227 (actual)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Ara-C
- **DRUG:** Rituximab
- **DRUG:** Thiotepa
- **RADIATION:** radiotherapy
- **DRUG:** BCNU
- **OTHER:** APBSCT

## Key facts

- **NCT ID:** NCT01011920
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-03
- **Final completion:** 2024-12-19
- **Target enrollment:** 227 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011920, "Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT01011920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*